Wils, P., Fumery, M., Nachury, M., Yzet, C., Coban, D., & Buisson, A. Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn’s disease. SAGE Publishing.
Chicago Style (17th ed.) CitationWils, Pauline, Mathurin Fumery, Maria Nachury, Clara Yzet, Dilek Coban, and Anthony Buisson. Switching from Intravenous to Subcutaneous Infliximab Is Safe and Feasible in Patients with Perianal Crohn’s Disease. SAGE Publishing.
MLA (9th ed.) CitationWils, Pauline, et al. Switching from Intravenous to Subcutaneous Infliximab Is Safe and Feasible in Patients with Perianal Crohn’s Disease. SAGE Publishing.
Warning: These citations may not always be 100% accurate.